Local Pensions Partnership Investment 13F: Adds $2.5M to MEDP Stake

Local Pensions Partnership Investment boosted its position in Medpace Holdings, Inc. (MEDP) by 4,000 shares, bringing its total to 46,000 shares. The information comes from the fund's latest Form 13F filing with the SEC, disclosed on October 26, 2026.

MEDP Medpace Holdings, Inc.

$676.77 ▲ +18.52% year to date

1M 3M YTD

Daily close · Oct 26, 2026

Where Medpace Holdings Fits in Local Pensions Partnership Investment's Portfolio

Medpace Holdings makes up 0.89% of Local Pensions Partnership Investment's reported portfolio. The fund ranks this position 15th out of its 33 holdings. The recent increase in shares represents a 9.5% change from the previous total of 42,000 shares.

Other Institutional Activity in Medpace Holdings

In recent activity, Fundsmith reduced its stake in Medpace Holdings by 19,899 shares, ending with 62,668 shares valued at about $33.2 million. Burney Co. opened a new position, acquiring 4,764 shares worth approximately $2.97 million. AQR Capital Management trimmed its holdings by 74,865 shares, leaving it with 1,278,935 shares valued at about $865.5 million.

Medpace Holdings, Inc. Stock Up 1.1%

On October 26, 2026, Medpace shares closed at $676.77, and as of October 27, they were recently traded around $676.80, which is about equal to the closing price. The stock is currently above its 50-day moving average by 10.3% and above its 200-day average by 28.2%, indicating strong performance.

Recent Earnings

Medpace reported trailing twelve months revenue of approximately $2.84 billion, with a year-over-year revenue growth of 8.5%. The next earnings report is scheduled for February 8, 2027.

Dividend

Medpace does not pay a dividend.

Insider Buying and Selling at Medpace Holdings, Inc.

Recently, August J. Troendle, the CEO, sold 10,880 shares at an average price of $620.40 on September 17, 2026, totaling about $6.75 million. He sold additional shares on September 22, 28, and 30, amounting to significant transactions.

Analysts Set New Price Targets

On October 23, 2026, several firms maintained their ratings on Medpace. UBS kept a Neutral rating with a target price of $700, while Truist Securities maintained a Hold rating with a target of $633. BMO Capital also maintained their Market Perform rating, setting a target of $670, which was updated on October 26, 2026.

About Medpace Holdings, Inc.

Medpace Holdings, Inc. provides clinical research services for drug and medical device development across various regions, including North America and Europe. The company supports clinical development phases from early trials to post-marketing.

Bottom Line

Investors should watch for Medpace's next earnings report on February 8, 2027, to gauge its ongoing performance. Local Pensions Partnership Investment's recent filing highlights its growing confidence in Medpace as part of its portfolio.